Phase 1 N=9 Pharmacokinetic Study of Vivitrol in Healthy Participants
Opioid-use Disorder
Primary: Median Cmax of Naltrexone (After 1st Dose) — 14.10 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=26 Phase I Study of MOv18 IgE
Human Cancers
Primary: Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) Considered to be at Least Possibly Related to MOv18 IgE — 0; 5; 2; 0 Participants
Phase 1 N=39 Pharmacokinetics and Hepatic Safety of EGCG
Uterine Fibroids
Primary: Changes in Epigallocatechin Gallate (EGCG) — 5.8; 256.3; 86.4 nM — p=0.112
Phase 1 N=33 A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
HIV Infections
Primary: Cohort 1: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC [0-inf]) of DTG, ABC and 3TC Following Administration of…
Phase 1 N=9 Safety, Tolerability, and Pharmacokinetics of IXT-m200
Healthy
Primary: Number of Participants With Treatment-related Adverse Events (AEs) Assessed by Physical Examinations — 0; 0 Participants
Phase 1 N=48 Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
Pulmonary TB
Primary: Local Injection Site Reactogenicity — 22; 21 participants
Phase 1 N=99 Encouraging Cognitive Screenings at African American Churches
Dementia · Healthy
Primary: Number of Participants Who Received a Cognitive Screening — 5; 11 Participants
Phase 1 N=16 The Interaction of Flavor With Nicotine Form in Adult Smokers
Nicotine Dependence
Primary: Changes in Liking of E-cigarette Overall — 14.2; 5.3; 11.9; 2.2 score on a scale — p=0.01
Phase 1 N=25 Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer
Solid Tumor
Primary: Maximum Observed Concentration (Cmax) of Pamiparib in Plasma for Part A — 1970; 1820 ng/mL
Phase 1 N=14 Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck · Carcinoma of the Head and Neck
Primary: Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling — 0; 4; 0; 0 Lymph Nodes
Phase 1 N=23 Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
HIV Infection
Primary: Number of Participants With Adverse Events — 1; 2; 3; 0 Participants
Phase 1 N=20 Study of Testosterone and rHGH in FSHD
Facioscapulohumeral Muscular Dystrophy
Primary: Number of Participants Who Experienced an AE — 14 Participants
Phase 1 N=16 Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
Chronic Kidney Disease
Primary: Maximum Plasma Concentration (Cmax) of Apraglutide — 39.5; 65.8 ng/mL
Phase 1 N=17 Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)
HIV-1 Infection
Primary: Number of Participants w/ at Least One ≥ Grade 3 Adverse Event That is Possibly or Definitely Related to Vorinostat (VOR) or HIV-specific T Cell (HXTC) — 0 Participants
Phase 1 N=176 To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Healthy
Primary: Pharmacokinetic Outcome Measures [AUC0-inf] for Part 2 — 910.9; 897.7; 926.3 day*μg/mL